Cargando…

SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies

Detalles Bibliográficos
Autor principal:	Martin, Malcolm A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848015/ http://dx.doi.org/10.1186/1742-4690-10-S1-O41

Ejemplares similares

Antibody mediated protection of immunized macaques against pathogenic SHIV challenge
por: Srivastava, Indresh K, et al.
Publicado: (2006)

Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2013)

MAb PGT121 protects against mucosal SHIV challenge in macaques at concentrations corresponding to its highly potent in vitro neutralization capacity
por: Moldt, B, et al.
Publicado: (2012)

OA021-02. Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV
por: Tangy, F, et al.
Publicado: (2009)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

Anti-CCR4 antibody activates virus specific immune response in STLV-1 infected Japanese monkey
por: Sugata, Kenji, et al.
Publicado: (2015)

Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from subtype-C HIV-1 infected north Indians; implications for MPER directed HIV-1 neutralization
por: Andrabi, Raiees, et al.
Publicado: (2012)

S021-05 OA. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
por: Song, L, et al.
Publicado: (2009)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies
por: Hora, Bhavna, et al.
Publicado: (2023)

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
por: Shingai, Masashi, et al.
Publicado: (2014)

Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
por: Krachmarov, C, et al.
Publicado: (2012)

Placental Hofbauer cells assemble and sequester HIV-1 in tetraspanin and DC SIGN positive compartments that are accessible to neutralizing antibodies
por: Johnson, Erica L, et al.
Publicado: (2014)

Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
por: Phogat, SK, et al.
Publicado: (2009)

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
por: Clumeck, Nathan, et al.
Publicado: (2006)

Non-neutralizing antibodies and vaccine-induced protection
por: Demberg, Thorsten, et al.
Publicado: (2006)

Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology
por: Nemazee, D, et al.
Publicado: (2012)

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018)

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
por: Hoffenberg, S, et al.
Publicado: (2012)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

Eliciting neutralizing antibodies with gp120 outer domain
por: Qin, Y, et al.
Publicado: (2012)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys
por: Moldt, Brian, et al.
Publicado: (2022)

Design clues from functional constraints and broadly neutralizing antibodies
por: Zhou, Tongqing, et al.
Publicado: (2006)

S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies
por: Loof, N, et al.
Publicado: (2009)

Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates
por: Moog, C, et al.
Publicado: (2012)

Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques
por: Gao, Nan, et al.
Publicado: (2020)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies
por: Shen, X, et al.
Publicado: (2009)

Natural and engineered antibodies against HIV
por: Berger, Edward A
Publicado: (2006)

Engineering chemokines to develop putative anti HIV-1 agents
por: Deepu, A, et al.
Publicado: (2012)

Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing
por: Zolla-Pazner, Susan, et al.
Publicado: (2006)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers
por: Hessell, Ann J., et al.
Publicado: (2009)

Neutralizing anti-HIV antibodies develop in a humanized mouse model of HIV-1 infection
por: Seung, E, et al.
Publicado: (2012)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)

Low intensity focused ultrasound modulates monkey visuomotor behavior
por: Deffieux, Thomas, et al.
Publicado: (2015)

Complete prevention of HTLV-1 infection in humanized mice (hu-PBL SCID) by a neutralizing monoclonal antibody to envelope gp46
por: Saito, Mineki, et al.
Publicado: (2014)

P03-10. Induction of neutralizing antibodies in Rhesus macaques following mucosal challenge with R5 tropic SHIV162P3 isolate
por: Chung, H, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_l1o5qfmeejc935lnef2tt8ukuc